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Abstract
The ABO and Rhesus blood group systems are the most clinically relevant blood 
group systems from haemolytic disease of the foetus and newborn (HDFN) and 
haemolytic transfusion reaction (HTR) perspectives. Other clinically relevant 
blood group systems include the Kell, Duffy, Kidd and MNSs blood group systems. 
The clinical relevance of a blood group system depends on the ability of antibodies 
of the system to cause HDFN and HTR. This chapter discusses the distribution 
of ABO, Rhesus and other clinically relevant red cell antigens among Nigerians 
and implications for HDFN and HTR. There are several challenges associated 
with the management of Rhesus negative pregnancies, pregnancies associated 
with clinically significant alloantibodies, implementation of policy on routine 
antenatal anti-D prophylaxis (RAADP), management of Rhesus negative women 
that require termination of pregnancy (TOP), provision of antigen negative blood 
for certain patient groups and the management of pregnant and non-pregnant 
patients with clinically significant alloantibodies. This chapter highlights the need 
for Nigeria and other African countries to implement best practices to optimize the 
care offered to pregnant women as well as patients in whom red cell transfusion is 
indicated.
Keywords: clinically relevant blood group antigens, Nigerians,  
rhesus D negative pregnancies, haemolytic disease of the foetus and newborn, 
haemolytic transfusion reaction
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1. Introduction
1.1 History of Nigeria
Nigeria often referred to the giant of Africa is the largest Black nation in 
Africa. It is a country located in West Africa bordered by Cameroon in the East, 
Benin Republic in the West, Niger Republic to the North and Chad Republic to the 
North East. It is a federation consisting of 36 states with Abuja the Federal Capital 
territory as the capital. It is located on the Gulf of Guinea with a total area of 
923,768 km2 (356,669 sq. miles). It is the world’s 32nd-largest country. Nigeria got 
her independence from the British on 1st of October 1960. It has an estimated popu-
lation of over 200 million people. The United Nations estimated the population in 
2016 to be 185,989,640 distributed as 51.7% rural and 48.3% urban with a popula-
tion density of 167.5 persons per square kilometre. Although the official language is 
English, there are more than 250 ethnic groups with well over 500 different native 
languages and diverse cultures. There are 3 major ethnic groups in Nigeria (Hausa/
Fulani, Igbo and Yoruba). Nigeria is a religiously diverse nation divided into a pre-
dominantly Christian South and Muslim North and a minority groups of traditional 
African religion. Nigeria is a mixed economy dependent and an emerging market. 
As at 2014 Nigeria was the fastest growing and largest economy in Africa. She is 
blessed with abundant natural resources and a developing communication, finan-
cial, legal and transportation sector. Nigeria is the 12th largest producer of oil in the 
world, the 8th largest exporter, has the 10th largest proven reserves and supplies 
a fifth of its oil to the United States of America. Oil plays a significant role in the 
Nigerian economy and accounts for 40% of GDP and 80% of all government earn-
ings. Healthcare delivery is the responsibility of the 3 tiers of government (federal, 
state and local government). There is a number of health-related challenges in 
Nigeria (HIV/AIDS, malaria, polio, poor access to potable and clean water, lack of 
proper sanitation system, high infant and maternal mortality rates). Although the 
recurrent expenditure on health in Nigeria has increased over the years, healthcare 
delivery and infrastructural endowment remains suboptimal with health tourism 
on the increase [1]. The Nigerian health care system is continuously faced with a 
number of challenges; shortage of healthcare workers [2] predominantly due to 
significant emigration of skilled medical personnel to developed economies of the 
world (brain drain), suboptimal funding, decaying infrastructure, inter-profes-
sional conflict, perennial strike actions by healthcare professionals, lack of political 
will as well as bureaucratic bottlenecks in public health care delivery in Nigeria [3].
2.  UHC and the WHO model lists as governmental obligations to 
implement before 2030
Nigeria is a party to the United Nation (UN) General Assembly adopted 2030 
agenda for Sustainable Development and the UN High-Level Meeting (UN HLM) 
Universal Health Coverage (UHC) UHC2030. In September 2015, the UN General 
Assembly adopted the 2030 Agenda for Sustainable Development that included 17 
Sustainable Development Goals (SDGs) ensuring that all persons are carried along 
and that no one is left behind [4]. The agenda laid emphasis a holistic approach 
aimed at achieving sustainable development for all. The 17 sustainable development 
goals (SDGs) included; no poverty, zero hunger, good health and well-being, quality 
education, gender equality, clean water and sanitation, affordable and clean energy, 
decent work and economic growth, industrial innovation and infrastructure, 
reduced inequality, sustainable cities and communities, responsible consumption 
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and production, climate action, life below water, life on land, peace and justice 
strong institutions and partnerships to achieve goal. On September 23rd 2019, a 
high-level meeting on universal health coverage held at the United Nations General 
Assembly. The meeting focussed on Universal Health Coverage: Moving Together 
to Build a Healthier World (UHC2030) and brought together heads of state, politi-
cal and health leaders, policy-makers, and universal health coverage champions 
to advocate for health for all. The meeting agreed on Key Asks from the UHC 
Movement aimed at accelerating progress toward Universal Health Coverage (UHC) 
[4]. Among others, UHC2030 advocates that countries should; ensure political 
leadership beyond health (that all countries to ensure healthy lives and wellbe-
ing for all at all stages as a social contract), leave no one behind (pursue equity in 
access to quality health services with financial protection), regulate and legislate 
(create a strong, enabling regulatory and legal environment responsive to people’s 
needs), uphold the quality of care (build high-quality health systems that people 
and communities trust), invest more and better (increased domestic investment 
and allocation of more public financing for health through equitable and manda-
tory resource) and move together (establishing multi-stakeholder mechanisms for 
engaging the whole of society for a healthier world). Nigeria is a party to the global 
commitment ensuring the well-being, universal health coverage and access to qual-
ity healthcare when and where they need it, without facing financial hardship [5]. 
There is general expectation among Nigerians for the government to mix word with 
action by ensuring that all Nigerians in both rural and urban communities have 
access and can use the promotive, preventive, curative, rehabilitative and palliative 
health services they require, that is of sufficient quality and affordable [6].
3. Current situation in Nigeria
3.1 Distribution of ABO and other clinically significant blood groups
The human red blood cell membrane is complex and contains a number of 
clinically relevant blood group antigens, the most relevant being the ABO and the 
Rhesus blood group antigens. Apart from the ABO and Rhesus blood group systems, 
thirty-four other blood group systems have been identified as at November 2014 [7]. 
In addition to the ABO and Rhesus blood group antigens, 364 other red cell antigens 
have been identified serologically. The clinical relevance of a blood group system 
depends on the distribution of antigens of the blood group system in the popula-
tion, ability of antibodies of the blood group system to cause haemolytic transfu-
sion reaction (HTR) and haemolytic disease of the foetus and newborn (HDFN) 
[8]. The ABO blood group system is one of the most clinically relevant blood group 
systems [9]. It was first discovered by Karl Landsteiner in 1901 [10]. The ABO blood 
group system has three main antigens (A, B and H). Four major ABO groups exist 
(A, B, AB and O). The ABO blood group system is based on the A and B antigens 
occurring singly as A or B, doubling as AB or the absence of both as O. Individuals 
who have lack the A or B antigens on their red cells have the group specific antibody 
in their serum or plasma. Antibodies of the system are predominantly IgM origi-
nally thought to be naturally occurring but are now known to occur in the first years 
of life as a result of sensitization to ABO-like antigen and environmental substances 
that occur in nature such as bacteria, viruses and food. Evidence has shown that 
these antibodies are not present at birth and that animals kept in a sterile room from 
birth do not produce these antibodies. The ABO blood group system is important in 
transfusion medicine, HDFN and in organ transplant. Transfusion of ABO incom-
patible unit can cause severe HTR. Similarly, an immune response can also occur 
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following ABO incompatible organ transplant. ABO blood group incompatibilities 
between the mother and child does not normally cause HDFN because antibodies 
of the ABO blood group system are usually of the large molecular weight IgM type, 
which do not cross the placenta. However, mothers who were previously sensitised 
(previous incompatible transfusion and pregnancy) can potentially have IgG ABO 
antibodies that can potentially cause ABO HDFN. The distribution of ABO blood 
groups varies across the world according to the population. There are also variations 
in blood type distribution within human subpopulations.
Nigeria is a significantly varied nation in terms of ethnicity. The gene frequency 
of ABO and Rh blood group varies significantly within the six geopolitical zones 
in Nigeria [11–18]. Previous studies in most parts of Nigeria indicates that the 
ABO blood group distribution is in the order O > A > B > AB [19]. Studies from 
the United States, Mauritania, Morocco, Cameroun, Tunisia, Ethiopia and Iran 
reported same order (O > A > B > AB) [20–26]. However, study in Madagascar and 
Guinea reported a contrary trend (O > B > A > AB) [27, 28]. This observation in 
Nigeria is also at variance with reports from India and Bangladesh where preva-
lence of B is highest followed by O and the least was AB (B > O > A > AB) [29, 30]. 
Reports from Turkey and Colombia indicates an order A > O > B > AB [31, 32].
A multi race/ethnic study in the United States reported that blood type O is the most 
prevalent (46.6%) with White non-Hispanic, Hispanic, Black non-Hispanic, Asian 
and North American Indian having varying percentage of 45.5, 56.5, 50.2, 39.8 and 
54.6 respectively [21]. Other studies in Turkey, Mauritania, Iran, Ethiopia, Colombia, 
Cameroun, Bangladesh, Madagascar, Morocco, Guinea and Northern India have 
reported varying percentage in ABO and Rh blood types [20–23, 25–32].
Phenotypic distribution of Rh(D) in Nigeria varies from one part of the coun-
try to the other; Kwara (4.5%) [17], Jos Plateau State (4.32) [14], FCT (4.3) [33], 
Minna (3.3%0) [11], Lagos (3.0, 6, 6.86%) [16, 34, 35], Ogun (6.65 and 2.9%) [36, 37], 
Osun (6.3%) [38], Oyo (3.3, 6.68, 4.8, 5.89%) [12, 14, 18, 39], Ekiti (4.3%) [40], Akwa 
Ibom (5.7%) [41], Bayelsa (2%) [42], Delta (1.8%) [43], Benin (6.0%) [13], Rivers (3.2, 
7, 8.3%) [44–46], Kano (5.2%) [47], Sokoto (1.55%) [14], Zamfara (1.2%) [48], Enugu 
(4.49%) [14], Abia (5.3%) [49], Ebonyi (4.2%) [50], Borno (1.92%) [14], Adamawa 
(4.6%) [51], Yobe (4.6%) [52]. The prevalence of Rhesus negativity varies from one 
zone to the other; 4.4, 3.1, 6.0, 4.3, 3.9 and 3.1% respectively for the South East, North 
East, South, South, South West, North Central and North West zone respectively.
The overall average prevalence of Rhesus negativity is 5.1%. The distribution of 
Rh(D) in Nigeria is in agreement with others parts of the world [20, 23, 25–28, 30, 
31]. Blacks have been found to have a lower frequency of Rhesus D negative pheno-
type (3–5%) [34, 42, 44] compared to the general Caucasian population (15%) [21, 
53]. The lower prevalence of Rh(D)− in Nigeria and other developing is important 
and a blessing in disguise because clinical situations like fetomaternal haemorrhage 
during the course of pregnancy can give arise through Rh incompatibility and 
HDFN. In Nigeria and many of these developing countries RAADP and other anti-D 
HDFN related prevention strategies are not being implemented. Table 1 shows the 
prevalence of Rhesus D group among Nigerians based on zones.
The Kell blood group is the third most clinically relevant blood group system 
after ABO and Rhesus. Individuals without Kell antigens (K0) who are transfused 
with Kell positive donor red cells or Kell negative pregnant women exposed to 
the Kell positive red cells of their baby carry the risk of developing Kell antibody 
which can cause HDFN [54]. In the developed world all pregnant women and 
non-pregnant women of child bearing age are transfused with Kell negative blood. 
Also, patients with other antibodies are transfused with Kell negative and red cells 
also lacking the antigen to which their alloantibody is specific. This is to prevent 
them from potentially developing anti-Kell antibody. Kell sensitization is the third 
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most common cause of HDFN after Rh and ABO. Anti-Kell has been shown to cause 
severe foetal anaemia by suppressing foetal RBC synthesis [55]. HDFN-associated 
anaemia in Anti-Kell-related HDFN is caused by the ability of anti-K to cause the 
suppression of foetal production of RBCs [56]. Unlike Rh and ABO, Kell antigens 
are expressed on the surface of RBC precursors, and anti-K promotes the immune 
destruction of Kell positive erythroid early progenitor cells by macrophages in the 
foetal liver rather than only mature foetal RBCs [55]. There are few Kell prevalence 
studies in Nigeria. Among their cohort of pregnant women in Sokoto, North 
Western Nigeria, Erhabor and Colleagues [57] obtained a Kell antigen prevalence of 
2%. Similarly, Ugboma and Nwauche [58] in Port Harcourt investigated the preva-
lence of Kell antigen among their patients and reported a Kell antigen prevalence 
of 2%. The prevalence of Kell antigen among a multi-ethnic cohort of 302 healthy 
Nigerian individuals indicated a zero prevalence of K antigen [59]. Racial differ-
ences seem to exist in Kell blood group antigen distributions [60, 61]. The Nigerian 
government and governments in other African countries will need to implement 
this strategy in a bid to reducing Kell-related sensitization and the effect of HDFN.
The prevalence of other clinically significant red cell antigens has been deter-
mined among Nigerians. The prevalence of Lewis, Kidd, Duffy, Kell and M blood 
group antigens among blood donors in Aminu Kano Teaching Hospital, Kano, 
Nigeria [62] were as follows: Lea: 26.4%, Leb: 15.1%, M: 20.8%, k (cellano): 21.7%. 
The Duffy (anti Fya, anti Fyb) and Kidd (anti Jka anti Jkb) antigens were not 
detected among the donors. Out of the 162 pregnant women tested for their Duffy 
antigens status indicated Fya, Fyb and Fya (a+b+) prevalence of 7 (4.3%), 9 (5.6%) 
and 1 (0.61%) respectively [63]. Kidd blood group phenotypes were determined 
among pregnant women in Sokoto, North Western Nigeria [63]. The distribution 
of Kidd antigens among subjects studied indicated a prevalence of Jka, Jkb and 
Jk(a+b+) of 8 (4.9%), 13 (8.0%) and 0 (0.0%), respectively. There is need for the 
phenotyping of donor’s blood for clinically significant red cell antigens. There is 
also the need to routinely screen all pregnant women for alloantibodies to facilitate 
the selection of antigen negative units for those with clinically significant alloanti-
bodies who require a red cell transfusion. This can potentially optimise the obstetric 
management of HDFN.
The prevalence of Rh c and e phenotype among 200 pregnant women attending 
antenatal clinic (ANC) in Usmanu Danfodiyo University Teaching Hospital Sokoto 
was determined. The prevalence of Rh c was 92% while Rh e was 98.5% [64]. 
The frequencies of Rh blood group antigens and phenotypes of the Ibibio, Efik, 
and Ibo ethnic nationalities in Calabar municipality, Nigeria, were determined 
using standard serologic techniques. Of the 720 Calabar individuals tested, the 
frequencies of the Rh antigens within the nationalities were c (100%), e (96.38%), 
Zone of 
Nigeria








Prevalence of Rhesus D group among Nigerians based on zones.
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D (96.38%), E (15.22%), and C (3.62%) for the Ibibios; c (100%), e (95.60%), D 
(96.70%), E (21.98%), and C (0%) for the Efiks; and c (100%), e (94.29%), D 
(91.43%), E (28.57%), and C (2.86%) for the Ibos. The overall frequencies of the 
Rh antigens in these 720 individuals were c (100%), e (95.56%), D (94.44%), 
E (18.89%), and C (2.78%). Forty (5.56%) were found to be D−, while all were 
found to possess the c antigen. The most frequently occurring Rh phenotype was 
Dccee, with a frequency of 73.61%. The alternative allele, C, did not appear in 
homozygous form (CC) in the population tested [65]. Of the 374 pregnant women 
studied in Port Harcourt, Nigeria, the frequencies of the Rh antigens within the 
population were D (89.0%), c (82.0%), e (54.0%), C (24.3%), E (20.1%). The 
frequencies of the Rh antithetical antigens were DD/Dd (91.2%), Cc (19.5%), cc 
(84.5%), Ee (13.9%), ee (54.3%), CC (25.1%), EE (19.8%) and dd (10.4%). Seven 
(1.9%) were found to be Rhnull, sixteen (4.3%) were found to be D− or exalted 
D. Phenotypes without RhD reactivity were -c- (2.9%), -Cc (0.3%), -C- (0.3%), 
-Ee (0.5%) and -E- (0.3%) [66]. A multi-ethnic cohort of healthy Nigerian 
individuals were studied. The antigen status of these individuals for Rh was 
determined. The prevalence of the Rh antigens in the study cohort was found to 
be: D (92.7%), C (20.5%), c (97.7%), E (19.5%), and e (97.4%). Dce was the most 
common Rh phenotype (53.3%) [59]. Few countries in sub-Saharan Africa have 
systematic testing for antigens C, c, E, and e of the Rh and Kell system antigens 
in the donor and recipient, thereby exposing transfused patients to the risk of 
developing antibodies that can cause HTR and HDFN. Among 651 blood donors 
tested in Abidjan for antigens of the Rh blood group system, the antigen frequen-
cies of D, c, e, C, and E were; 92.93, 99.85, 99.85, 21.97, and 13.82% respectively. K 
antigen is was found in 0.77% of donors [67].
3.2  Universal donor phenomenon: the need to implement a policy of universal 
haemolysin testing of group O donor units
ABO blood group system is one of the most clinically relevant blood group 
systems. Individuals above the age of 6 months have clinically significant anti-A 
and/or anti-B in their serum particularly if they lack the corresponding antigens on 
their red cells. Whole blood transfusion still thrives in Nigeria despite the advan-
tages of component therapy and challenges associated with whole blood transfu-
sion (development of febrile transfusion reactions, graft-versus-host disease, 
alloimmunization to leukocyte antigens, immunomodulatory effects, transmission 
of diseases such as cytomegalovirus, Human T-Lymphotrophic Virus I/II and 
Epstein Barr (EBV) for which leukocytes may be the vector) [68]. Blood group O 
donor blood is the most common blood group among Nigerian blood donors [69] 
and their red cells are commonly used as universal donor units for transfusion to A, 
B and AB recipient particularly in emergency situations. Blood group O individu-
als lack the A and B antigens on their red cells and thus are inappropriately called 
Universal donors. These individuals have anti A and Anti B in the plasma. Due to 
the absence of A and B on their red cell, their red cells could be given to A, B, and 
AB individuals. This is quite useful particularly in Nigeria and other developing 
countries where there is inadequate supply of donor blood. However, some group 
O individuals have potentially lytic anti-A and lytic anti-B in their plasma that bind 
to antigens A and B on the surface of erythrocytes in recipients and potentially 
activate the complement cascade resulting in acute intravascular haemolysis. To 
avoid this, all blood group O donor units intended for transfusion to non-O patient 
must be tested for the presence of these anti-A and lytic anti-B haemolysis. Those 
donors found negative can have their blood given to non-O patients while those 
that test positive are reserved for group O recipients only. Haemolysin testing to 
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identify the presence of haemolytic anti-A and anti-B antibodies has emerged as 
a useful screening in most countries to identify high levels of anti-A and/or anti-B 
antibodies to prevent HTRs. Routine haemolysis testing of blood group O donor 
units intended for transfusion to A, B or AB recipient is not routinely carried out 
in most settings in Nigeria despite the high prevalence of haemolysins observed 
among Nigerians in previous studies [70–75]. The Nigeria government can learn 
from evidenced-based best practices in most developed settings [76, 77] and imple-
ment a policy to routinely test all group O donor units for haemolysins in other to 
identify group O donors with high titre of IgG anti A and/or anti B whose blood 
should be reserved only for transfusion to group O recipient while those that test 
negative can be transfused to A, B or AB individual as a way to maximising the use 
of our limited allogeneic stock.
3.3 Screening for clinically significant alloantibodies
Alloantibodies are antibodies produced in a patient as a result of exposure 
to foreign red cell antigen via transfusion, pregnancy or transplantation. In 
countries such as Nigeria, there are multiple ethnic groups and racial or genetic 
heterogeneity among the population. This can often be associated with a wide 
variation of alloantibodies [78]. Other common factors that facilitate alloanti-
body formation in the recipient include: the immune competence, the dose of 
the antigen the recipient is exposed to, the route of exposure and how immuno-
genic the foreign antigen is [79, 80]. Development of alloantibodies can lead to 
difficulty in finding compatible blood for transfusion or it can result in severe 
delayed haemolytic transfusion reaction if the antibody titre is low, undetected, 
missed and if antigen positive units is transfused [81]. Evidenced-based best 
practice in the developing world requires that alloantibody testing is carried out 
as part of pre-transfusion testing of patients who require a red cell transfusion 
as well as pregnant women presenting to antenatal clinic at booking [82, 83]. 
The aim of this test is to detect the presence of unexpected red cell antibody 
in the patient’s serum [84, 85]. Once these antibodies are detected during the 
alloantibody screening, every effort must be made to identify the specificity of 
the alloantibody by doing a panel test. The aim of identifying the specificity of 
the alloantibody in a patient that requires a red cell transfusion is to enable the 
Medical Laboratory or Biomedical Scientist to select antigen negative donor unit 
for appropriate crossmatch (indirect antiglobulin test) for such patient [86]. The 
aim of a panel test in the case of a pregnant women coming for antenatal booking 
is to identify the alloantibody, determine whether the antibody can potentially 
cause HDFN [87] and to allow the monitoring of the titre or quantification of 
the antibody every 4 weeks from booking until 28 weeks’ gestation and every 
2 weeks thereafter until delivery [88]. The obstetrician requires this information 
to determine to what extent the developing foetus is affected by HDFN, decide 
whether to monitor the baby for anaemia using Doppler ultrasound, determine 
whether the baby will require intrauterine transfusion and to make an informed 
decision to possibly deliver the baby earlier. These evidence-based best practices 
are not being implemented in many settings in Nigeria. Testing of donor units 
for other clinically relevant red cell antigens other than ABO and Rhesus D is not 
routinely carried out. Also, donor units particularly those intended for transfu-
sion to pregnant women and neonates are also not routinely screened for CMV 
and Hepatitis E virus like it is routinely done in more advanced part of the world. 
This is a complete failure in stewardship by the Nigerian government and can 
compromise the transfusion service delivery to pregnant women and patients 
that require red cell transfusion.
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4. Challenges for the future
4.1  Absence of universal access to prophylactic anti-D through the routine 
antenatal anti-D prophylaxis (RAADP) program
RAADP or routine antenatal anti-D prophylaxis is a recommended treatment 
option for all Rhesus D negative pregnant women who are not known to be sensi-
tised previously to the RhD antigen. The D antigen is the most immunogenic and 
most clinically relevant of the Rhesus antigens. A mother who is RhD negative and 
married to a homozygous or heterozygous D positive husband has a 100 and 50% 
chance respectively of carrying a D positive baby. During such pregnancies as a 
result of feto maternal haemorrhage (FMH) following potentially sensitising events 
[abdominal trauma, abortion or termination of pregnancy, antepartum haemor-
rhage (APH), amniocentesis, chorionic villus sampling, external cephalic version 
(ECV) and miscarriages] during pregnancy, small amounts of foetal blood can 
enter into the maternal circulation. The foetal RhD-positive cells can irreversibly 
sensitise the mother to produce alloantibody D. The risk of sensitisation occurring 
is dependent on a number of factors; ABO blood group of the developing foetus 
(there is a higher risk if there is ABO compatibility between mum and baby), dose 
of foetal cells entering the maternal circulation, immune competence of the mother 
and type of pregnancy (risk is significantly higher in the first decreasing in the 
subsequent pregnancies. The antibody produced is immune IgG antibody that is a 
low molecular weight antibody and can potentially cross the placenta barrier. The 
maternal immune anti-D are small molecular weight IgG immunoglobulin and can 
pass through the placenta in subsequent D positive pregnancy and destroy the foetal 
red cells with increased production of bilirubin a product of red cell breakdown 
(HDFN). While in womb the mother manages the bilirubin on behalf of the baby 
by production of glucoronyl transferase enzyme which break down (conjugate) 
the bilirubin to water soluble forms that can be excreted in the urine. However, 
after delivery, the excess bilirubin released from the breakdown of the foetal red 
cells leads to jaundice. With the baby’s liver poorly developed and not producing 
enough glucoronyl transferase enzyme to conjugate the bilirubin to excretable form, 
the level can potentially rise above the blood brain barrier and cause kernicterus 
(permanent brain damage) with attendant neurodevelopmental problems (cerebral 
palsy, deafness neuromotor and speech delay). Routine antenatal anti-D prophy-
laxis (RAADP) is a program under which Rhesus D negative non-sensitised preg-
nant women are universally offered anti-D prophylaxis at 28–34 weeks’ gestation 
with the aim of preventing the sensitization of Rh D-negative women and by exten-
sion prevent anti-D HDFN in subsequent pregnancy [89]. The aim of the RAADP 
programme is the reduction in the incidence of anti-D related HDFN; improve 
the survival of the children delivered by Rhesus D negative women, reduce the 
incidence of disability and health-related quality of life of children and mortality in 
children delivered by Rhesus D negative women who would have developed anti-D 
related-HDFN if mothers were not offered prophylaxis. The RAADP program is 
based on offering either two doses of at least 500 IU at 28- and 34-weeks’ gestation 
or a single dose of at least 1500 IU at 28 weeks gestation followed by a further dose 
of at least 1500 IU within 72 h of delivery of a Rh D positive baby. The dose offered 
post-delivery is dependent on the result of feto maternal haemorrhage testing 
result (flow cytometry of Kleihauer testing). Both methods quantify in millilitres 
the amount of foetal red cells that has entered maternal circulation to facilitate the 
administration of adequate dose of prophylactic anti-D. As a general rule 1 25 IU 
of anti-D is administered to clear 1 ml of foetal red cells from maternal circula-
tion. The introduction of anti-D prophylaxis using Rhesus D immunoglobulin 
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(given intramuscular or intravenous administration) has led to a significant fall in 
the number of women becoming sensitised and by extension reduced the incidence 
and severity of this condition. The anti D immunoglobulin used as prophylaxis 
is prepared from plasma of male Rhesus D negative donors who have high levels 
of plasma anti-D due to deliberate or intentional immunisation with D positive 
red cells. Anti D is also administered to Rhesus D negative women following a 
potentially sensitising events during pregnancy. The anti-D facilitates the clearance 
of foetal red cells from the maternal circulation to prevents active immunisation, 
thus preventing the production of alloantibody D. Prior to the availability and 
widespread use of anti-D prophylaxis for Rhesus negative pregnant women, the 
incidence of Rh D sensitization among Rhesus D negative women following two 
deliveries of D positive and ABO-compatible, infants was approximately 16% and 
haemolytic disease of the foetus and newborn (HDFN) due to immune anti-D was 
a significant cause of morbidity and mortality [90]. Following the implementation 
of anti-D prophylaxis, the rate of sensitization has declined significantly to approxi-
mately 2%. With the implementation of RAADP by providing anti-D prophylaxis 
in the 3rd trimester between 28 and 34 weeks gestation, there has been a further 
remarkable reduction in the sensitisation rate to 0.17–0.28% [91]. Mortality from 
D-related HDFN related has also declined significantly from 46/100,000 births to 
1.6/100,000 births [89]. Evidence from best practice implementation in England 
and Wales indicates that RAADP has reduced the incidence of sensitisation and 
hence of HDFN [92]. Conservative estimate indicates that it cost £2–£3.5 million for 
England and Wales to provide RAADP to all her Rh D-negative pregnant women. 
The Nigerian government can learn from this evidence-based best practice by 
implementing RAADP program for her population of Rhesus D negative pregnant 
population with the hope of reducing sensitization, incidence and severity of anti-D 
related HDFN and mortality in Nigeria.
4.2  Absence of facility for foetal genotype testing for D, K and other clinically 
relevant red cell antigens
Rhesus D grouping is relevant for blood donors, transfusion recipients and for 
women of child bearing age including pregnant women. This is because the Rh 
blood group antigens particularly D is significantly immunogenic. Rh D negative 
individuals often lack the D antigens on their red cells and can potentially be sen-
sitised when exposed to D antigen positive red cells during pregnancy and blood 
transfusion. Such antibodies are often capable of causing a haemolytic transfusion 
reaction (HTR) and haemolytic disease of the foetus and newborn (HDFN). Since 
the introduction of prophylactic anti-D and implementation of evidence based 
best practice of careful management and monitoring of D negative pregnant 
women for all the potentially sensitising events that occur during pregnancy, the 
prevalence of HDFN because of Rh D incompatibility between the mother and 
baby has declined significantly [90]. In order to prevent Rhesus D negative women 
who are not previously sensitised from developing alloantibody D, these women 
are offered prophylactic anti-D during pregnancy under the Routine Antenatal 
Anti-D Prophylaxis program between 28 and 34 weeks’ gestation. The half-life of 
the administered anti-D is 12 weeks. The anti-D prevents the mother from being 
sensitised by micro foetal maternal haemorrhage that can occur as a result of 
potentially sensitising events that occur during pregnancy. These women should 
have a fetomaternal haemorrhage testing following any potentially sensitising 
events that occur after from 20 weeks’ gestation. This test quantifies the amount 
of foetal red cells that entered the maternal circulation to allow for the adminis-
tration of adequate dose of anti-D to clear the fotal cells and prevent them from 
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sensitising the mother. Anti-D (125 IU) is required to remove 1 ml of foetal red 
cells from maternal circulation. RhD alloimmunisation is still a significant cause 
of foetal and neonatal morbidity and mortality particularly in Nigeria and other 
developing countries [93–95] because of absence of evidence-based best practices 
and non-implementation of Rh D prophylaxis during pregnancy. This often result 
in a significant number of unfortunate women developing alloantibody D through 
no fault of theirs but rather as a result of failure in stewardship by the Nigerian 
government. Also, non-invasive foetal blood group genotyping (DNA) testing of 
maternal plasma to determine the antigen status of the developing foetus carried 
by an alloimmunised pregnant women is vital as it provides useful information 
as to whether a foetus is carrying the group specific antigen and in fact at risk of 
HDFN. This will help prevent the need for extensive laboratory testing (titration 
and quantification of antibody every 4 weeks from booking till 28 weeks’ gestation 
and every 2 weeks from 28 weeks to delivery) and clinical monitoring in antigen 
negative cases. Molecular testing of maternal plasma for foetal DNA can be per-
formed during the second trimester. DNA probes for the most common antigens 
associated with HDFN are now available [96]. Knowledge of the molecular basis 
of the blood group systems has facilitated the development of assays for blood 
group genotyping. Foetal Rhesus D genotyping can potentially tell at 16 weeks’ 
gestation through the analysis of amniotic fluid or through maternal plasma 
the foetal D genotype of the developing foetus. In previously sensitised alloim-
munised pregnant women, knowledge of the foetal D antigen status is beneficial 
to enable obstetricians optimally manage these women [95]. In non-sensitised 
Rhesus negative pregnant women, the knowledge of the foetal D antigen status 
is quite important for several reasons; prevent us from exposing the mother to a 
prophylactic anti-D (a human blood product that even though significantly virally 
tested for TTIs) she does not need, allow for the optimal utilisation of the product 
in patients in whom it is indicated and spare the woman the pain of the product 
being administered intramuscularly. RHD genotyping of foetuses carried by Rh 
D-negative women using foetal DNA obtained invasively through amniocentesis 
or chorionic villus sampling used to be critical to the clinical management of these 
women. Technological advances now allows for accurate determination of foetal 
Rh D genotype using cell-free foetal DNA from maternal blood, thus overcoming 
the invasive procedures [97]. Rh D genotyping are based on polymerase chain reac-
tion using non-invasive blood sample from the mum are quite sensitive with low 
incidence of false positive result [98, 99]. Although there are cases of D-negative 
genomes possessing fragments of mutated Rh D genes, the most notable of which 
is the Rh D pseudogene found in Africans. Rh D genotyping tests have been devel-
oped to differentiate these alleles and thus enhance the diagnosis in a multi-ethnic 
population [100].
Foetal blood group genotype of a developing foetus can also be determined for 
Rh C, c, E and Kell (K) using cffDNA from maternal plasma [101]. Many European 
Union countries have suggested the mass application of foetal genotyping for all 
foetuses carried by D-negative women. This advocacy is based on clear benefit of 
conserving anti-D stocks and prevention of unnecessary administration of this 
human-derived blood product that has associated risk [102, 103]. In Denmark 
and the Netherlands this evidenced-based best practice of foetal Rh D testing for 
all non-sensitised D negative pregnant women have been introduced [104]. Also, 
non-invasive foetal blood group genotyping (DNA) testing of maternal plasma to 
determine the antigen status of the developing foetus carried by an already alloim-
munised pregnant women is vital as it provides useful information as to whether 
a foetus is carrying the group specific antigen and in fact at risk of haemolytic 
disease. This will help prevent the need of extensive laboratory (titration and 
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quantification of antibody every 4 weeks till 28 weeks’ gestation and every 2 weeks 
from 28 weeks to delivery) and clinical monitoring in antigen-negative cases.
4.3  Absence of facility for intrauterine transfusion for children with HDFN that 
are severely anaemic in utero
The maternal alloantibody D produced as a result of sensitization of the Rh 
D negative mother to the Rhesus D positive foetal red cells are low molecular 
weight IgG antibody. This antibody can potentially cross the placenta barrier into 
the foetal circulation and can destroy the foetal red cells resulting in anaemia, 
heart failure, hydrops foetalis (fluid retention and swelling) and intrauterine 
death. In utero the diagnosis of foetal anaemia used to be made by carrying out 
ultrasound guided foetal blood sampling for analysis of the foetal haemoglobin 
and haematocrit or amniocentesis-an invasive ultrasound guided procedure with 
a significant 2% risk of foetal loss associated with entering the amniotic sac and 
obtaining amniotic fluid which is analysed for product of haemoglobin break-
down. However, non-invasive diagnosis of foetal anaemia can now be made using 
non-invasive Doppler ultrasound technology by measuring the middle cerebral 
artery peak systolic velocities (MCA PSV). The foetal anaemia can be managed 
with intrauterine blood transfusions. Intrauterine transfusion is associated with a 
number of risks; foetal bradycardia, foetal death, cord haematoma, haemorrhage 
from the puncture site, miscarriage, preterm labour and vessel spasm. The blood 
used for such transfusions must meet certain requirements; gamma irradiated red 
cells to prevent transfusion-associated graft-versus-host disease, haemoglobin S 
negative, CMV negative and significantly high PCV (0.70–0.85) [105, 106], unit 
must be C-, D-, E- and K-, leucocyte depleted to less than 1 × 106 leucocytes per 
unit, less than 5 days old, free from clinically significant irregular blood group 
antibodies and negative for high-titre anti-A and anti-B haemolysin. If the mother 
has other alloantibodies apart from D, it is vital that suitable unit negative for the 
specific antigens to which those maternal alloantibodies are specific are selected. 
Once the baby is delivered, intensive phototherapy and IV immunoglobulin along 
with antiglobulin (DAT) test should be carried out. There should also be continu-
ous monitoring of the haemoglobin, haematocrit and bilirubin level. A positive 
DAT is diagnostic of HDFN and the baby sample should be sent for elution to 
identify if the antibody coating the foetal red cell is maternal alloantibody. If the 
bilirubin is not responsive to intensive phototherapy and continues to rise, the 
associated neonatal anaemia and hyperbilirubinemia can be managed by carrying 
our exchange blood transfusion (EBT) to prevent bilirubin encephalopathy by 
removing a significant number of maternal antibodies-coated foetal red cells and 
excess bilirubin and replacing it with donor red cells. The red cell product used for 
EBT must meet certain requirements; group O or ABO compatibility (mum and 
baby), compatible with any maternal antibody, gamma irradiated, collected in 
saline, adenine, glucose and mannitol (SAGM), fresh less than 5 days old, have high 
haematocrit (0.5–0.55) to prevent of post-exchange anaemia and polycythaemia 
and negative for high titre haemolysins. A number of these evidenced-based best 
practices; facility for intrauterine blood transfusion, facilities for diagnosis of 
foetal anaemia in utero, maternal alloantibody testing, elution testing, facility for 
gamma irradiation of blood, CMV testing of donors units, testing of donor units 
for other clinical significant red cell antigens apart from ABO and Rhesus D, SAGM 
units and leucodepletion of donor units are often not available in Nigeria and most 
developing countries. This failure in stewardship by government in these countries 
limits the delivery of best possible care in the management of HDFN and appropri-
ate transfusion in these patients.
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4.4  Absence of facility to monitor the antibody titre and quantification in 
pregnant women who have developed HDFN causing alloantibody during 
pregnancy
Haemolytic Disease of the Foetus and Newborn (HDFN) is the destruction of 
foetal and newborn red cells by maternally derived alloantibody directed against a 
red cell antigen often inherited from the father and expressed on foetal cells. These 
maternal IgG antibodies are low molecular weight and can pass through the pla-
centa barrier into the foetal circulation and bind to the corresponding foetal red cell 
antigen. The resultant maternal IgG-coated cells interact with foetal macrophages 
in resulting in their removal by the foetal spleen. This often results in anaemia, 
erthroblastosis with compensatory erythropoiesis resuming in the foetal liver and 
spleen, resulting in hepatosplenomegaly and portal hypertension. Maternal 
antibody screening is undertaken to detect clinically significant antibodies, which 
might affect the foetus and/or newborn, and to detect antibodies that may cause 
problems with the provision of compatible blood products for the woman and for 
the foetus/newborn. Approximately 1% of pregnant women are found to have 
clinically significant red cell antibodies [107–109]. The detection of clinically 
significant antibodies among antenatal women plays an important role in transfu-
sion safety and preventing HDFN. A previous study among antenatal multiparous 
women in Jammu region of India indicated that the commonly observed alloanti-
bodies were anti-D, anti-E, anti-C and anti-K [110]. Once an antibody has been 
detected, it is identified by carrying out a panel test. If the antibody specificity is 
one that has the potential to cause HDFN, the titre/quantification must be carried 
out periodically. Antibody quantification and titration is performed on patients’ 
samples, to support the prediction and management of HDFN and ABO mis-
matched organ transplant. Antibody quantification of anti-D, and anti-c for 
management of HDFN. Antibody titration in ABO mismatched transplant is 
carried out to allow clinical assessment of the possibility of carrying out an ABO 
mismatched transplant, and monitoring of treatment to reduce antibody titre in 
preparation for ABO mismatched transplant. All clinically significant maternal 
antibodies detected during antenatal booking or follow up visit must be referred to 
the reference laboratory for confirmation of specificity, determination of the 
possibility of the antibody to cause HDFN and for and titre/quantification to allow 
for the monitoring of antibody. Evidence based best practice in developed countries 
requires the monitoring of women with red cell antibodies of specificities known to 
have potential to cause significant HDFN (anti-D, anti-c and anti-K), covering 
frequency of testing (every 4 weeks from booking until 28 weeks and every 2 weeks 
there after till delivery), measurement of antibody concentration (by quantifica-
tion or titration as appropriate), referral to a foetal medicine specialist and follow-
up required post-delivery. Antibodies that require quantification include anti-c, 
anti D, anti c + D, and anti-c + E. The antibodies that require titration include 
Anti-e, c, E, C+ e, G, CW, Fya, Fyb, K, k, Kpa, Kpb, Jsa, Jsb, M, S, and s. Antibody 
titration (ABT) is a semi quantitative method used to detect the strength of an 
alloantibody/antibodies present in the patient’s plasma [111]. Antibody titration is 
used prenatally to screen for risk of HDFN, haemolytic transfusion reactions and 
assessment in solid organ or haematopoietic stem cell transplant. To assess risk for 
HDFN, the titre of the clinically significant alloantibody is performed. When the 
antibody and the titre strength are identified, ABT is periodically performed 
throughout pregnancy, whereby plasma samples are compared in parallel with the 
previously frozen samples to determine if the titre or strength of the antibody is 
static, decreasing or increasing. Obstetricians can use this information in conjunc-
tion with middle cerebral artery Doppler assessment to determine the extent to 
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which the developing infant is affected, the presence of foetal anaemia, decision to 
carry out intrauterine transfusion as well as decision on whether to deliver the baby 
earlier to allow for a better and less risky physical management rather than ultra-
sound-guided in utero management [112]. Colour Doppler ultrasonography a 
non-invasive technique is currently being used to assess cerebral artery blood flow 
[113]. Increased cerebral artery blood flow is an indicator of foetal anaemia [114]. 
Invasive procedures such as amniocentesis or cordocentesis, with subsequent 
analysis of amniotic fluid and foetal blood sampling obtained by ultrasonography 
guided procedure are invasive and significantly risky with potential attendant 
negative effect to the foetus. Accepted titration methodologies include the tube and 
gel column technology method [115]. A difference of 2 dilutions or a score of 10 is 
usually an indication of significant change in antibody production. The antibody 
titre/quantification often rises as a result of re-exposure of the maternal immune 
system to red cell antigen following the initial sensitising events that occur during 
pregnancy. Every re-exposure to the initial offending antigen from the foetus to the 
mother’s immune system often becomes booster doses. These booster doses often 
result in more antibody production, attendant increase in the titre and quantifica-
tion. Antibody titration is also commonly used for screening blood products, 
particularly platelets and plasma as well as group O donor blood intended for 
transfusion to blood group A, B and AB patients. This is to decrease the risk of 
haemolytic transfusion reactions due to passive anti-A/anti-B antibodies. The titre 
of group O products is determined and those with high titers [51, 114] are labelled 
and used for group O individuals only while those negative for HT haemolysin can 
be given to A, B and AB individuals [116]. Also, ABT also has a potential role in 
preventing graft rejection in ABO-incompatible solid organ transplants (heart, 
liver, and lung) [117] as well as in erythroid engraftment after haematopoietic 
progenitor cell transplants [118]. Previous report indicates that the performance of 
antenatal titrations by column agglutination technology (CAT) is at least as sensi-
tive as the performance by the indirect antiglobulin test (IAT) tube method. CAT 
was found to show greater sensitivity than IAT tube when dealing with anti-c 
compared to titrating Anti-K. The CAT method also appears to be more sensitive 
for detecting samples that require referral to the obstetrician [119]. Evidenced-
based best practice requires that all pregnant women are tested for the presence of 
alloantibodies and its titers/quantification during pregnancy as a way of calculating 
the risk of developing HDFN [120]. Guidelines of the British Committee for 
standards in Haematology requires that, all pregnant women should be ABO and D 
antigen typed and screened for presence of alloantibodies at booking and at the 
28th week of gestation [121]. Similarly, in the Netherlands, it has been mandatory 
to screen all pregnant females for presence of alloantibodies [122]. The aim of 
periodic antibody titration and quantification (every 4 weeks from detection at 
booking till 28 weeks and every 2 weeks thereafter until delivery) is to determine 
whether the titre/quantification is static, decreasing or increasing. A static titre/
quantification shows that there is no increase in severity over time, a dropping 
titre/quantification indicate a low risk for HDFN while a rising titre/quantification 
is an indication of a potentially severe HDFN. For anti-D quantification a level of 
4–15 IU indicates a moderate risk while a level > 15 IU indicates a high risk for 
HDFN. For anti-c a level > 7.5 IU indicates a high risk of HDFN. For anti-K, a titre 
of 1:32 or greater is indicative of HDFN risk. Generally, a 4-fold increase in the titre 
of an HDFN-associated alloantibody is an indication of a significant risk for HDFN 
[68]. In Nigeria and some other African countries alloantibody testing at booking 
and at 28 weeks gestation is not available, facilities for alloantibody identification 
and titration/quantification is not available. A number of pregnant women have 
alloantibodies without knowing and the risk of mortality from HDFN is high. 
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Nigerian and most of these countries can afford to provide the best possible 
antenatal care for their pregnant population like it obtains in the developed world. 
However, lack of political will, failure in stewardship and endemic corruption and 
misappropriation of the people’s resources remains a major challenge to the effec-
tive management of the women. African government must rise to the responsibili-
ties and do what is right by implementing evidence-based practice to allow for the 
effective management of pregnancies associated with clinically significant alloanti-
bodies and its associated HDFN.
4.5  Challenge associated with use of anti-D immunoglobulin for the prevention 
of haemolytic disease of the foetus and newborn
Alloantibody-D are produced in a woman of child bearing age either as a result 
of Rhesus D incompatible transfusion (deliberate or erroneous transfusion of D 
positive donor red cells to Rhesus D negative women) or as a result of prior Rhesus 
D incompatibility between the mother and the developing foetus. These sensitiza-
tions are often as a result of fetomaternal haemorrhage during pregnancy or during 
delivery. This is often associated with D positive red cells entering into the maternal 
circulation to sensitise the mother to produce these immune antibody D. This 
immune D is an IgG class antibody and can potentially cross the placenta in subse-
quent D positive pregnancies to cause D HDFN. If a Rhesus D negative woman is 
married to Rh D positive men who are either homozygous or heterozygous for blood 
group antigen D, there is a 100 and 50% chance respectively of potentially carry-
ing a Rhesus D positive foetus. In such pregnancies the risk of sensitization of the 
mother during the first pregnancy as a result of fetomaternal haemorrhage (during 
pregnancy or delivery) of D positive foetal red cell into maternal circulation is high. 
The recommend that prophylaxis be provided as soon as possible and always within 
72 h of the following potentially sensitising event taking place in Rh D negative 
pregnant women (Amniocentesis, chorionic villus biopsy and cordocentesis, APH, 
PV bleed during pregnancy, ECV, Abdo trauma (sharp/blunt, open/closed, ectopic 
pregnancy, evacuation of molar, pregnancy, IUFD, intrauterine intervention during 
pregnancy (transfusion, surgery, insertion of shunts and laser), miscarriages, TOP, 
delivery (normal, instrument or C/S) and intraoperative cell salvage) to prevent 
sensitization and anti-D-related HDFN in subsequent pregnancy. Evidence-based 
best practice in most developed countries is to prevent this sensitization from 
taking place by the implementation of the Routine Antenatal Anti-D Prophylaxis 
(RAADP) programme. This program is alloimmunization prevention where all 
Rh D negative women are universally offered anti prophylaxis during pregnancy 
(28 weeks gestation) and following the delivery of a Rhesus positive baby. The 
implementation of this program has significantly reduced the number of residual 
alloimmunization from 16% to less than 0.1% [123]. The justification for this 
implementation is based of scientific evidence that 92% of women who develop an 
alloantibody-D during pregnancy do so at or after 28 weeks gestation [124, 125].
This implementation has significantly reduced the number of women who are 
sensitised and by extension the number of D HDFN. However, in countries like 
Nigeria and some other developing countries where this policy has not been imple-
mented, a significant 14% of unfortunate foetuses are born dead while 50% of those 
who are born alive suffer from brain injury and neonatal death [126]. This cases of 
preventable death of Nigerian and African children is a humanitarian emergency 
that require urgent attention and good will by the Nigerian, African government 
and people of good will across to globe. Rho(D) immune globulin (RhIG) is a medi-
cation that can be given to non-sensitised Rhesus D negative pregnant women to 
prevent Rh D sensitization. The medication is often administered intramuscularly 
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or intravenously and has a half-life of 12 weeks. Rho(D) immune globulin used for 
prophylaxis is a human derived fractionated plasma product produced from blood 
donors who have high levels of anti-D Ig either due to previous sensitization or 
intentional immunisation of Rh D negative men to produced immune D. This prod-
uct is significantly virally tested (HBsAg, anti-HIV and HCV RNA) and includes 
viral inactivation steps in order to further reduce the risk of viral transmission. 
There is still a small unquantifiable possibility of transmitting prion particularly 
vCJD or other infectious agents. Product safety data submitted by manufacturers 
to National Institute of Health and Clinical Excellence technical appraisal guidance 
156 (National Institute for Health and Clinical Excellence [127]) indicates a very 
low rate of adverse event (less than one non-serious per 80,000 doses of anti-D 
administered) [89]. There is no evidence till date to suggest that prophylactic anti-D 
administered to Rhesus D negative women during pregnancy is harmful to the 
foetus. Child birth or delivery is a potential sensitising event that can potentially 
expose the mother to the Rhesus D positive cells of the baby. Following delivery in 
these women, the cord blood is tested for ABO, Rh D group and DAT. If the infant 
is Rhesus D positive, the mother sample taken within 72 h is tested for fetomaternal 
haemorrhage (flow cytometry of Kleihauer-Betke test). These tests quantify the 
number of foetal cells that has entered the maternal circulation and thus facilitates 
the determination of the optimal dosage of prophylactic anti-D to be administered. 
As a general rule 125iu of anti-D is required to clear 1 ml of foetal cells from mater-
nal circulation. A dose of 300 μg or 1500 IU is often sufficient to prevent alloim-
munization after delivery in 99% of cases [128]. If the D-type of a newborn or 
stillborn is unknown or cannot be determined, a dose of anti-D prophylaxis should 
be administered. However, if the infant is found Rhesus D negative, prophylaxis 
will not be required. Evidenced-based best practices in most developed countries as 
part of their HDFN prevention program recommend the following [92].
In Nigeria and many countries in Africa, these recommendations and best prac-
tices are not being implemented. Government in these countries will need to rise 
up to their responsibilities by implementing these recommendations to prove the 
sincerity of their resolve to offer their people particularly Rhesus negative women 
the best possible health care delivery.
4.6 Unaffordability due to high cost of prophylactic anti-D
Anti-D related HDFN often result from the transplacental passage of maternal 
allo-antibodies directed against foetal red cell antigens inherited from the father 
affects the foetus or neonate. Majority of the mothers becomes sensitised following 
small feto-maternal haemorrhages during pregnancy and at delivery of the first Rh 
D-positive infant. These antibodies can potentially cause HDFN in successive Rh 
D-positive infants. Implementation of universal access to prophylactic anti-D given 
during antenatal and post-partum period following the delivery of a Rh D positive 
baby can help prevent primary Rh D immunisation and risk of HDFN in subsequent 
pregnancies [129]. It is recommended that routine antenatal anti-D prophylaxis 
(RAADP) is offered to all non-sensitised pregnant women who are Rh D negative to 
reduce the risk of sensitization and by extension D-related HDFN [130]. The World 
Health Organisation (WHO) recommends that antenatal prophylaxis with anti-D 
immunoglobulin should be given to non-sensitised Rh-negative pregnant women 
at 28 and 34 weeks of gestation to prevent Rh D alloimmunization. It is estimated 
that single dose of anti-D can cost around US$ 50 (500 IU) to US$ 87 (1500 IU), 
depending on the brand and local taxes. Therefore, the cost of antenatal prophy-
laxis for two 500 IU doses could be as much as US$ 100 per woman. Additional 
costs will include screening for blood typing in settings where Rh blood tests are not 
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currently performed [131]. However, providing anti-D prophylaxis universally to all 
Rh D negative non-sensitised pregnant women is not cheap. The cost benefit analy-
sis of preventing sensitization, HDFN and its related physical disabilities, mental 
retardation and death of affected children supports investing in the implementation 
of this policy by responsible government who believes that every life count. Routine 
antenatal anti-D prophylaxis provides a cost effective intervention for preventing 
HDFN in non-sensitised Rh D-negative pregnant women [132]. Health economic 
model indicates a significant cost per quality-adjusted life-year (QALY) gained by 
the implementation of RAADP given to Rh D-negative primigravidae versus no 
RAADP is between £9000 and £15,000, and for RAADP given to all RhD-negative 
women rather than to Rh D-negative primigravidae only is between £20,000 and 
£35,000. It is suggested that a programme of routine prophylaxis would be cost 
saving if HDFN were eradicated by its implementation [130]. The National Institute 
for Health and Clinical Excellence reported that when RAADP for all Rh D-negative 
women was compared with that for primigravidae, the additional cost per incident 
of sensitisation prevented ranged from £2900 to £8200 depending on the regimen 
used. The cost per HDFN-associated foetal loss avoided was £42,000–120,000. It 
does make economic sense for African government to rise to their responsibilities 
by proving universally anti-D prophylaxis to all non-sensitised Rhesus D negative 
women. There is also potential to significantly reduce the cost of implementing 
RAADP by these governments investing on facilities to non-invasive determination 
of foetal D genotyping for all non-sensitised Rh D negative pregnant women. This 
will help identify women who are carrying Rhesus D negative mothers who will 
not require the prophylaxis. Also, because the prevalence of Rh D negative status is 
significantly lower among Nigerians (6%) [133] compared to the West ≥15% [134], 
it is likely to cost African countries a lot less to implement universal access to anti-D 
prophylaxis [135].
4.7  Challenges associated with the provision of antigen negative red cells to 
patients with clinically significant red cell antibodies
Evidenced based best practice in management of patients including pregnant 
women requires that patients are transfused with red cells lacking the group 
specific antigens to which the recipient alloantibody is specific [136]. This aim 
of this implementation is to prevent immune mediated destruction of the donor 
red cells containing the offending antigen [137, 138]. For example, pregnant 
women who have alloantibody Kell should be given K-negative donor units. The 
provision of antigen negative blood units for these patients is a special challenge 
particularly in Nigeria and many other countries in Africa [139]. Although these 
countries have national blood transfusion services, majority of them are often 
not fit for purpose. Majority of them test blood donors only for their ABO and 
Rhesus antigen status [139]. Routine testing of blood donors for other clinically 
significant red sell antigens are not routinely done. This has a significant implica-
tion on haemolytic transfusion reaction and HDFN. In the alloimmuned pregnant 
women who have low molecular weight immune IgG antibodies, IAT crossmatch-
ing should ideally be carried out using donor red cells suspended in low ionic 
strength saline preferably using highly sensitive column agglutination technique 
instead of the conventional less sensitive tube methods. Many of these technolo-
gies are often not available in most settings in Nigeria and other African countries. 
Transfusion of antigen positive donor red cells to patient with the group specific 
antibodies like it potentially happens in Nigeria and some other African countries 
have significant negative consequences [140]. These antibodies can cause clini-
cally significant haemolytic transfusion reactions, difficulty in cross-matching 
17
Distribution of Clinically Relevant Blood Group Antigens among Nigerians and the…
DOI: http://dx.doi.org/10.5772/intechopen.90372
blood and getting compatible blood in future, cause decrease in RBC survival and 
thus negate the aim of red cell transfusion of managing anaemia, improving the 
quality of life and improving the oxygen carrying capacity of the recipient’s blood 
[141]. Also, there is also the effect of managing donor red cell clearance and the 
product of red cell breakdown due to haemolysis which often results in multiple 
organ failure, electrolyte perturbations, coagulopathy and in some severe cases, 
death [142]. Nigerians and citizens of other African countries deserve the best 
quality transfusion service like their counterparts in the West. It is the responsi-
bility of African government to work smartly and effectively by avoiding waste 
and eradicating corruption to ensure that citizens get the best quality health care 
they deserve.
4.8 Lack of facilities for feto-maternal haemorrhage testing
The accurate detection and quantification of foetal red blood cells (RBCs) in the 
maternal circulation are necessary for the prevention of Rhesus D alloimmuniza-
tion among D-negative women because of FMH. It is critical to the administration 
of adequate amount of anti-D prophylaxis are necessary for the prevention of 
Rhesus D alloimmunization. As a result of D incompatibility between mother 
(Rhesus D negative and foetus (D-positive), foetal red cells can enter into maternal 
circulation and sensitise the mother to produce anti-D alloantibody. These anti-
D alloantibodies (small molecular weight IgG antibodies) can pass through the 
placenta barrier in subsequent D positive pregnancies cause HDFN (haemolysis, 
foetal anaemia, hydrops foetalis, kernicterus or even death). FMH testing helps 
obstetrician to determine that a potential sensitising event has taken place and 
facilitate the administration of adequate amount of prophylactic anti-D (125 IU 
per 1 ml bleed of foetal red cells into maternal circulation). The widespread use of 
FMH testing in the evidenced-based provision of adequate immunoprophylaxis 
with anti-D immunoglobulin has resulted in a significant reduction in the incidence 
of anti-D related HDFN mortality. Evidence-based best practice implementation 
of FMH test and provision of immunoprophylaxis with anti-D immunoglobulin 
in England and Wales has brought about a significant reduction in the number of 
infants affected with HDFN from affected in 1.2 per 1000 births in 1970 to 0.02 
per 1000 births by 1989. There are several methods available for FMH testing 
(Quantitative and qualitative). Three qualitative methods (micro Du, rosette test, 
and PEG Du) and two quantitative methods (acid elution and Flow Cytometry) 
for assessing FMH were evaluated with particular attention given to PEG Du and 
FC. Of the qualitative techniques, the micro Du test was the least sensitive with 
20% false-negative results occurring at 0.5% foetal cells. The PEG Du test was only 
slightly more sensitive and offered no clinical advantage. The rosette test was the 
most sensitive, consistently detecting foetal cells at concentrations of 0.25% or 
greater. Flow Cytometry and acid elution showed similar results, with good corre-
lation obtained between measured and expected quantities of foetal cells (r = 0.99 
and 0.96, respectively). One of 26 postpartum samples was positive by all screening 
techniques; acid elution and FC detected 0.3% concentrations of fetal cells and 
0.17% [143, 144]. The rosette screen is a highly sensitive in qualitatively detecting 
10 mL of foetal whole blood in the maternal circulation. As the screen is reliant on 
the presence of the D antigen to distinguish foetal from maternal cells, it cannot 
be used to detect FMH in D-positive mothers or in D-negative mothers carrying a 
D-negative fetus. The Kleihauer-Betke acid-elution test, the most widely used con-
firmatory test for quantifying FMH, relies on the principle that foetal RBCs contain 
mostly foetal haemoglobin (HbF), which is resistant to acid-elution whereas adult 
haemoglobin is acid-sensitive. Although the Kleihauer-Betke test is inexpensive 
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and requires no special equipment, it lacks standardisation and precision, and may 
not be accurate in conditions with elevated F-cells. Flow cytometry is a promising 
alternative, although its use is limited by equipment and staffing costs. The two 
well-established confirmatory tests are the Kleihauer-Betke acid-elution assay and 
flow cytometry. The rosette screen is a highly sensitive FDA approved method 
to qualitatively detect 10 mL or more of foetal whole blood, or 0.2% foetal cells 
(volume/volume) in the maternal circulation [143]. The principle is based upon the 
formation of microscopic foetal D+ aggregates upon incubation of foetal cells with 
enzyme0-treated group O D-positive indicator RBCs and reagent anti-D serum. 
The foetal cells must be D-positive and the maternal cells D-negative for the test to 
be valid. In summary the maternal blood sample is first incubated with anti-D and 
then washed. The indicator D-positive RBCs are added and the sample is examined 
under a light microscope. In the presence of anti-D coated foetal D-positive cells, 
the indicator cells will form aggregates (or rosettes) around the foetal cells. The 
main limitation of this method is that falsely positive result may occur is the mum 
has a variant of the D antigen and falsely negative if the foetus or neonate is weak 
D. Also, mothers that have a positive direct antiglobulin test (DAT) or an autoan-
tibody can produce a false positive result due to the agglutination of the mother’s 
antibody coated red cells.
A positive rosette test is indicative of FMH > 10 mL. In a negative rosette test 
administration of is 300 μg (1500 IU) of Rh Ig is sufficient to prevent immunisation 
in 99% of patients. If the rosette test is positive quantification of the FMH by either 
the Kleihauer-Betke acid elution test or flow cytometry is indicated to determine 
the optimal dose of prophylactic anti-D immunoglobulin to be administered. The 
Kleihauer-Betke acid-elution test is an inexpensive method and requires no spe-
cial equipment and thus can possibly be implemented in developing country like 
Nigeria and other resource-limited settings. The method is based on the principle 
that foetal RBCs containing foetal haemoglobin (HbF) to resist acid elution whereas 
adult haemoglobin does not. When a peripheral smear prepared from a EDTA anti-
coagulated maternal blood sample is exposed to an acid buffer such as Shepherds 
stain, haemoglobin in the cytoplasm of maternal red cells are eluted while HbF in 
the foetal red cells resist acid elution. Subsequent counterstaining with haema-
toxylin results in red cell containing foetal haemoglobin staining pink while the 
maternal adult haemoglobin containing red cells appear as ghost. Figure 1 shows 
a positive Kleihauer-Betke test. To calculate the number of foetal cells in maternal 
circulation using Kleihauer-Betke test, get a stained thin film on a microscope and 
replace one of the objectives of the microscope with a graticule (Miller square) 
(Figure 2). Focus the microscope making sure the graticule is on the top left-hand 
corner. Select the ×40 lens and count at least 50 fields of the area of the film where 
the red cells are just touching each other. For each field count all the foetal cells in 
the large and small square. Count all the maternal cells in the small square. Count 
fields with at least 25–30 maternal cells. To calculate the total number of maternal 
cells, add the total number of maternal cells together and multiply by 9. Also add 
the total number of foetal cells from the 50 fields. The calculation of FMH is done 
using Mollison’s rule.
Mollison’s rule = 2400 × number of foetal cells ÷ number of maternal cells
For example, if the number of foetal red cells is 20 and the maternal cells is 
2000, the FMH = number of maternal cells = 2000 × 9 = 18,000
25 × 2400/18,000 = 3.3 mls bleed.
Calculation of dose of anti-D. Anti-D administered is calculated by giving 125 IU 
per ml of FMH. For a 3.3 ml bleed you will have to administer 3.3 × 125 IU = 413 IU 
of anti-D.
19
Distribution of Clinically Relevant Blood Group Antigens among Nigerians and the…
DOI: http://dx.doi.org/10.5772/intechopen.90372
The Kleihauer-Betke method is a labour intensive and subjective method. The 
accuracy and precision of this method is hampered by lack of standardisation 
which can potentially lead to slight variations in result (thickness of blood smear, 
pipetting skill of analyst, pH variations in the buffer used, inter analyst varia-
tions). Over- and underestimation of FMH using the Kleihauer-Betke test has 
been reported [145, 146]. The disadvantages of this method include; laborious to 
perform, lacks standardisation, is imprecise and may not be accurate in conditions 
associated with elevated haemoglobin F containing red cells. However, standardisa-
tion of the Kleihauer-Betke test can make the result potentially comparable to result 
from flow cytometry [147]. Haemoglobin F containing red cells are increased in 
haemoglobinopathies including sickle cell disease and β-thalassemia and hereditary 
persistence of foetal haemoglobin (HPFH). In 25% of pregnant women, HbF tend 
to be increased and can cause false positive results [148, 149]. In pregnant women 
with conditions such as sickle cell disease, thalassaemia and HPFH an alternative 
method for FMH testing such as flow cytometry should be employed. Despite its 
limitations, a good correlation has been reported between the Kleihauer-Betke test 
and flow cytometry for both small and large FMH [150, 151].
Flow cytometry involves using a flow cytometer using monoclonal antibodies 
directed against. Flow cytometric determination of FMH is superior to Kleihauer-
Betke test for a number of reasons; cytometric methods can accurately distinguish 
adult foetal haemoglobin containing red cells from foetal RBCs, flow cytometers 




Diagram of Miller square (graticule).
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its quantitative accuracy and flow cytometry is automated non-subjective and has 
greater reproducibility. The only disadvantage is that it requires trained staff to 
perform test coupled with the fact that it is it is expensive and may not be affordable 
in low-resource settings.
5. Conclusions
There is paucity of data on the distribution of clinically significant blood group 
antigens apart from ABO and Rhesus D among Nigerians. Management of Rhesus D 
negative pregnancies and pregnancies associated with clinically significant alloan-
tibody is suboptimal. This failure in stewardship by the Nigerian government has a 
significant implication for Haemolytic Disease of the Foetus and Newborn and hae-
molytic transfusion reaction. There is need to introduce routine screening of pregnant 
women in Nigeria for clinically significant red cell antibodies to facilitate the effective 
management of HDFN as well as prevent HTR by enabling the selection of antigen 
negative red cells for women who have alloantibodies and require a red cell transfusion.
5.1 Recommendations
We recommend that the Nigerian government should implement the following 
evidence-based best practices (British Committee for Standards in Haematology 
[152–155].
1. That the Nigerian government should fulfil her obligations under goal 3.8 of 
the Universal Health Coverage initiative and the Sustainable Development goal 
3.b which emphasises the need for access to safe, effective, quality and afford-
able essential medicines for all by implementing universal access to anti-D 
prophylaxis for previously unsensitized Rhesus D negative pregnant women.
2. Screen donor units for clinically significant antigen status to facilitate the 
selection of antigen negative donor units for transfusion to patients with a 
clinically significant alloantibody.
3. Routinely screening all blood group O donors whose units are intended for 
transfusion to non-O recipients for high titre haemolysin.
4. Anti-D immunoglobulin should be available in cases of potentially sensitising 
events such as amniocentesis, cordocentesis, antepartum haemorrhage, vaginal 
bleeding during pregnancy, external cephalic version, abdominal trauma, in-
trauterine death and stillbirth, in utero therapeutic interventions, miscarriage, 
and therapeutic termination of pregnancy.
5. All Rhesus D negative women having a termination of pregnancy (abortion) 
must be tested for Rhesus D group and those found to be Rhesus D negative 
must be offered prophylaxis following the procedure.
6. Routine foetal genotyping using non-invasive testing of maternal sample to 
identify Rhesus negative pregnant women who are carrying Rhesus negative 
infants for whom prophylaxis is not indicated.
7. Facilities for intrauterine transfusion of infants who become anaemic in utero 
as a result of HDFN and require a red cell transfusion. Facilities to test donor 
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red cells to ensure that they meet the requirements for intrauterine, exchange 
and top up transfusion.
8. Facilities for the implementation of alloantibody titration and quantification 
should be provided for pregnant women with a clinically significant, HDFN 
causing alloantibody.
9. There is need for the provision of facilities for fetomaternal haemorrhage test-
ing to facilitate the administration of optimal amount of anti-D prophylaxis 
following a sensitising event to prevent HDFN.
10. Knowledge of anti-D prophylaxis and management of women with clini-
cally significant antibodies among Obstetricians, Laboratory of Biomedical 
Scientist, Midwives, Traditional Birth Attendants, Pharmacists and Nurses in 
Nigeria and other countries in Africa needs to be improved. This will facilitate 
quality antenatal and postnatal care offered particularly to Rh-negative preg-
nant women and those with clinically significant alloantibodies.
11. That anti-D prophylaxis be provided in Rhesus D negative pregnant pregnan-
cies <12 weeks gestation, following ectopic pregnancy, molar pregnancy, thera-
peutic termination of pregnancy. FMH haemorrhage (FMH) testing is often 
not required for sensitising events at <12 weeks gestation.
12. That for all potentially sensitising events occurring between 12- and 20-weeks’ 
gestation, prophylaxis should be administered within 72 h of the event without 
need for FMH testing.
13. That for potentially sensitising events after 20 weeks gestation, prophy-
laxis should be administered within 72 h of the event along with testing for 
FMH. This is to determine if additional dose of anti-D Ig is required for a 
significant bleed.
14. That in the event of an intrauterine foetal death (IUFD), where no sample can 
be obtained from the baby or foetus, an appropriate dose of prophylactic anti-
D should be administered to Rhesus D negative, previously non-sensitised 
women within 72 h of the diagnosis of IUFD, irrespective of the time of subse-
quent delivery.
15. That following intra-operative cell salvage (ICS) during Caesarean section in 
D negative, previously non-sensitised women, and where cord blood group is 
confirmed as D positive (or unknown), a minimum dose of 1500 IU prophy-
lactic anti-D should be administered following the re-infusion of salvaged 
red cells. Also, the maternal sample should be taken for estimation of FMH 
30–45 min after reinfusion to confirm if a further dose of anti-D Ig is required.
16. That in cases of therapeutic termination of pregnancy (abortion), whether by 
surgical or medical methods, and regardless of gestational age, all previously 
non-sensitised D negative women should receive a dose of prophylactic anti-D 
within 72 h of having the procedures.
17. That anti-D prophylaxis should be administered to all cases of ectopic preg-
nancy in previously non-sensitised, D negative women regardless of the mode 
of management.
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18. That there is significant potential for sensitisation in cases of molar pregnancy. 
Anti-D prophylaxis should be administered to all cases of molar pregnancy in 
previously non-sensitised, D negative women.
19. That D negative women presenting with continual uterine bleeding between 
12- and 20-weeks’ gestation should be offered anti-D prophylaxis at a mini-
mum of 6 weekly intervals.
20. That under normal circumstances, D negative platelets should be transfused to 
D negative females or women of child bearing age, who need a platelet trans-
fusion. Occasionally, if the appropriate product is not available or its avail-
ability is likely to cause unacceptable delay and harm, it may be necessary to 
transfuse D positive platelets. In these situations, prophylaxis against possible 
sensitisation by the D positive red cells contaminating the platelet product 
should be given. A dose of 250 IU anti-D immunoglobulin is sufficient to cover 
up to five adult therapeutic doses of D positive platelets given over a 6-weeks 
period.
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